Diabetic cardiomyopathy: an update of mechanisms contributing to this clinical entity

G Jia, MA Hill, JR Sowers - Circulation research, 2018 - Am Heart Assoc
Heart failure and related morbidity and mortality are increasing at an alarming rate, in large
part, because of increases in aging, obesity, and diabetes mellitus. The clinical outcomes …

The tubular hypothesis of nephron filtration and diabetic kidney disease

V Vallon, SC Thomson - Nature Reviews Nephrology, 2020 - nature.com
Kidney size and glomerular filtration rate (GFR) often increase with the onset of diabetes,
and elevated GFR is a risk factor for the development of diabetic kidney disease …

Glucose transporters in brain in health and disease

H Koepsell - Pflügers Archiv-European Journal of Physiology, 2020 - Springer
Energy demand of neurons in brain that is covered by glucose supply from the blood is
ensured by glucose transporters in capillaries and brain cells. In brain, the facilitative …

Physiology of renal glucose handling via SGLT1, SGLT2 and GLUT2

C Ghezzi, DDF Loo, EM Wright - Diabetologia, 2018 - Springer
The concentration of glucose in plasma is held within narrow limits (4–10 mmol/l), primarily
to ensure fuel supply to the brain. Kidneys play a role in glucose homeostasis in the body by …

Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition

V Vallon, SC Thomson - Diabetologia, 2017 - Springer
Healthy kidneys filter∼ 160 g/day of glucose (∼ 30% of daily energy intake) under
euglycaemic conditions. To prevent valuable energy from being lost in the urine, the …

Empagliflozin, a sodium glucose co-transporter-2 inhibitor, alleviates atrial remodeling and improves mitochondrial function in high-fat diet/streptozotocin-induced …

Q Shao, L Meng, S Lee, G Tse, M Gong… - Cardiovascular …, 2019 - Springer
Background Diabetes mellitus is an important risk factor for atrial fibrillation (AF)
development. Sodium–glucose co-transporter-2 (SGLT-2) inhibitors are used for the …

Functional and clinical importance of SGLT2-inhibitors in frailty: from the kidney to the heart

G Santulli, F Varzideh, I Forzano, S Wilson… - …, 2023 - Am Heart Assoc
SGLT2 (sodium-glucose cotransporter 2) enables glucose and sodium reabsorption in the
kidney. SGLT2-inhibitors (also known as gliflozins, which include canagliflozin …

SGLT2 protein expression is increased in human diabetic nephropathy: SGLT2 protein inhibition decreases renal lipid accumulation, inflammation, and the …

XX Wang, J Levi, Y Luo, K Myakala… - Journal of Biological …, 2017 - ASBMB
There is very limited human renal sodium gradient-dependent glucose transporter protein
(SGLT2) mRNA and protein expression data reported in the literature. The first aim of this …

The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus

V Vallon - Annual review of medicine, 2015 - annualreviews.org
The kidneys in normoglycemic humans filter 160–180 g of glucose per day (∼ 30% of daily
calorie intake), which is reabsorbed and returned to the systemic circulation by the proximal …

[HTML][HTML] SGLT-2 inhibitors in cancer treatment—mechanisms of action and emerging new perspectives

M Dutka, R Bobiński, T Francuz, W Garczorz, K Zimmer… - Cancers, 2022 - mdpi.com
Simple Summary Despite significant advances in the treatment of cancer, it remains a major
cause of death worldwide and new treatment options are constantly being sought. An …